Combined GADD45A and thymidine phosphorylase expression levels predict response and survival of neoadjuvant-treated gastric cancer patients

Clinical Cancer Research

Volumn 11, Issue 8, 2005, Pages 3025-3031

  Napieralski, Rudolf ^a   Ott, Katja ^a   Kremer, Markus ^a   Specht, Katja ^a   Vogelsang, Holger ^a   Becker, Karen ^a   Müller, Martina ^a   Lordick, Florian ^a   Fink, Ulrich ^a   Siewert, Jörg Rüdiger ^a   Höfler, Heinz ^a,b   Keller, Gisela ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b INSTITUTE OF EPIDEMIOLOGY   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN DERIVATIVE; FLUOROURACIL; FOLINIC ACID; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45; THYMIDINE PHOSPHORYLASE;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DATA ANALYSIS; EVALUATION; FEMALE; GENE EXPRESSION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; STOMACH BIOPSY; STOMACH CANCER; TUMOR BIOPSY;

ADULT; AGED; ANTIGENS, NUCLEAR; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; CISPLATIN; DIHYDROURACIL DEHYDROGENASE (NADP); DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NUCLEAR PROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STOMACH NEOPLASMS; SURVIVAL ANALYSIS; THYMIDINE PHOSPHORYLASE; THYMIDYLATE SYNTHASE; TREATMENT OUTCOME;

EID: 20244379716     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-1605     Document Type: Article

References (42)

1. Ajani JA, Mansfield PF, Lynch PM, et al. Enhanced staging and all chemotherapy preoperatively in patients with potentially resectable gastric carcinoma. J Clin Oncol 1999;17:2403-11.
2. Lordick F, Stein HJ, Peschel C, Siewert JR. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg 2004;91:540-51.
3. Parker WB, Cheng YC. Metabolism and mechanism of action of 5-fluorouracil. Pharmacol Ther 1990;48:381-95.
4. Terashima M, Irinoda T, Fujiwara H, et al. Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer. Anticancer Res 2002;22:761-8.
5. Ishikawa Y, Kubota T, Otani Y, et al. Dihydropyrimidine dehydrogenase and messenger RNA levels in gastric cancer: possible predictor for sensitivity to 5-fluorouracil. Jpn J Cancer Res 2000;91:105-12.
6. Choi J, Lim H, Nam DK, et al. Expression of thymidylate synthase in gastric cancer patients treated with 5-fluorouracil and doxorubicin-based adjuvant chemotherapy after curative resection. Br J Cancer 2001;84:186-92.
7. Yeh KH, Shun CT, Chen CL, et al. High expression of thymidylate synthase is associated with the drug resistance of gastric carcinoma to high dose 5-fluorouracil-based systemic chemotherapy. Cancer 1998;82:1626-31.
8. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998;16:309-16.
9. Lenz HJ, Leichman CG, Danenberg KD, et al. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. J Clin Oncol 1996;14:176-82.
10. Kikuyama S, Inada T, Shimizu K, Miyakita M, Ogata Y. p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer. Anticancer Res 2001;21:2149-53.
11. Terashima M, Fujiwara H, Takagane A, et al. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer. Gastric Cancer 2003;6:71-81.
12. Pinto AL, Lippard SJ. Binding of the antitumor drug cis- diamminedichloroplatinum(II) (cisplatin) to DNA. Biochim Biophys Acta 1985;780:167-80.
13. McHugh PJ, Sones WR, Hartley JA. Repair of intermediate structures produced at DNA interstrand cross-links in Saccharomyces cerevisiae. Mol Cell Biol 2000;20:3425-33.
14. Frit P, Canitrot Y, Muller C, et al. Cross-resistance to ionizing radiation in a murine leukemic cell line resistant to cis- dichlorodiammineplatinum(II): role of Ku autoantigen. Mol Pharmacol 1999;56:141-6.
15. Smith ML, Kontny HU, Bortnick R, Fornace AJ Jr. The p53-regulated cyclin G gene promotes cell growth: p53 downstream effectors cyclin G and Gadd45 exert different effects on cisplatin chemosensitivity. Exp Cell Res 1997;230:61-8.
16. Ott K, Vogelsang H, Mueller J, et al. Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin Cancer Res 2003;9:2307-15.
17. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003;21:4604-10.
18. Becker K, Mueller JD, Schulmacher C, et al. Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy. Cancer 2003;98:1521-30.
19. Ott K, Sendler A, Becker K, et al. Neoadjuvant chemotherapy with cisplatin, 5-FU, and leucovorin (PLF) in locally advanced gastric cancer: a prospective phase II study. Gastric Cancer 2003;6:159-67.
20. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001;19:3058-65.
21. Specht K, Richter T, Muller U, Walch A, Werner M, Hofler H. Quantitative gene expression analysis in microdissected archival formalin-fixed and paraffin-embedded tumor tissue. Am J Pathol 2001;158:419-29.
22. Rosivatz E, Becker I, Specht K, et al. Differential expressionof the epithelial-mesenchymal transition regulators snail, SIP1, and twist in gastric cancer. Am J Pathol 2002;161:1881-91.
23. Uchida K, Hayashi K, Kuramochi H, Takasaki K. Changes in intratumoral thymidylate synthase (TS) and dihydropyrimidine dehydrogenase (DPD) mRNA expression in colorectal and gastric cancer during continuous tegafur infusion. Int J Oncol 2001;19:341-6.
24. Andersen CL, Jensen JL, Orntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res 2004;64:5245-50.
25. Hilsenbeck S, Clark G. Practical P-value adjustment for optimally selected cutpoints. Stat Med 1996;15:103-12.
26. Farrugia DC, Ford HE, Cunningham D, et al. Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed. Clin Cancer Res 2003;9:792-801.
27. Hirano Y, Takayama T, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Thymidine phosphorylase and dihydropyrimidine dehydrogenase in renal cell carcinoma: relationship between histological parameters and chemosensitivity to 5-fluorouracil. Eur Urol 2003;43:45-52.
28. Noguchi T, Fujiwara S, Takeno S, et al. Clinical impact of thymidine phosphorylase expression in gastric cancer. Oncol Rep 2003;10:561-6.
29. Saito H, Tsujitani S, Oka S, et al. The expression of thymidine phosphorylase correlates with angiogenesis and the efficacy of chemotherapy using fluorouracil derivatives in advanced gastric carcinoma. Br J Cancer 1999;81:484-9.
30. Salonga D, Danenberg KD, Johnson M, et al. Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 2000;6:1322-7.
31. Ishikawa F, Miyazono K, Hellman U, et al. Identification of angiogenic activity and the cloning and expression of platelet-derived endothelial cell growth factor. Nature 1989;338:557-62.
32. Sato J, Sata M, Nakamura H, et al. Role of thymidine phosphorylase on invasiveness and metastasis in lung adenocarcinoma. Int J Cancer 2003;106:863-70.
33. Kitazono M, Takebayashi Y, Ishitsuka K, et al. Prevention of hypoxia-induced apoptosis by the angiogenic factor thymidine phosphorylase. Biochem Biophys Res Commun 1998;253:797-803.
34. Smith ML, Chen IT, Zhan Q, et al. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. Science 1994;266:1376-80.
35. Ichikawa W, Uetake H, Shirota Y, et al. Combination of dihydropyrimidine dehydrogenase and thymidylate synthase gene expressions in primary tumors as predictive parameters for the efficacy of fluoropyrimidine-based chemotherapy for metastatic colorectal cancer. Clin Cancer Res 2003;9:786-91.
36. Hirano Y, Kageyama S, Ushiyama T, Suzuki K, Fujita K. Clinical significance of thymidine phosphorylase and dihydropyrimidine dehydrogenase expression in transitional cell cancer. Cancer Chemother Pharmacol 2003;51:29-35.
37. Terashima M, Fujiwara H, Takagane A, et al. Role of thymidine phosphorylase and dihydropyrimidine dehydrogenase in tumour progression and sensitivity to doxifluridine in gastric cancer patients. Eur J Cancer 2002;38:2375-81.
38. Ishikawa Y, Kubota T, Otani Y, et al. Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. Anticancer Res 1999;19:5635-40.
39. Shintani Y, Ohta M, Hirabayashi H, et al. New prognostic indicator for non-small-cell lung cancer, quantitation of thymidylate synthase by real-time reverse transcription polymerase chain reaction. Int J Cancer 2003;104:790-5.
40. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
41. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-16.
42. Lowy AM, Feig BW, Janjan N, et al. A pilot study of preoperative chemoradiotherapy for resectable gastric cancer. Ann Surg Oncol 2001;8:519-24.